Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice

Blood
Carol H MiaoH D Ochs

Abstract

A robust humoral immune response against human factor VIII (hFVIII) following naked DNA transfer into immunocompetent hemophilia A mice completely inhibits circulating FVIII activity despite initial high-level hFVIII gene expression. To prevent this undesirable response, we compared transient immunomodulation strategies. Eight groups of mice (n = 4-9 per group) were treated with naked DNA transfer of pBS-HCRHPI-hFVIIIA simultaneously with immunosuppressive reagents that included cyclosporine A (CSA), rapamycin (RAP), mycophenylate mofetil (MMF), a combination of CSA and MMF, a combination of RAP and MMF, a monoclonal antibody against murine CD40 ligand (MR1), recombinant murine Ctla4Ig, and a combination of MR1 and Ctla4Ig. All animals except those receiving only CSA exhibited delayed or absent immune responses against hFVIII. The most effective immunosuppressive regimen, the combination of Ctla4Ig and MR1, prevented inhibitor formation in 8 of 9 animals; the ninth had transient low-titer antibodies. All 9 mice of this group produced persistent, therapeutic levels of hFVIII for more than 6 months. When challenged with the T-dependent antigen bacteriophage Phix174, tolerized mice exhibited normal primary and secondary antibody r...Continue Reading

References

Feb 1, 1975·Experimental Parasitology·G M Dooris, R B McGhee
Jun 1, 1990·Immunology Today·C H JuneC B Thompson
Aug 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·J J TooleR J Kaufman
Aug 15, 1993·The Journal of Immunology : Official Journal of the American Association of Immunologists·T J CurielR L Berens
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·L ChatenoudJ F Bach
Jan 1, 1993·Annual Review of Immunology·P S Linsley, J A Ledbetter
May 1, 1996·Immunity·R J Noelle
Apr 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A KayC B Wilson
Jan 10, 1998·American Journal of Hematology·A G BroxM Pelletier
May 20, 1998·Proceedings of the National Academy of Sciences of the United States of America·G L Evans, R A Morgan
May 4, 1999·The Journal of Clinical Investigation·J R AbramsS Kang
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·T VandenDriesscheM K Chuah
Apr 26, 2000·Haemophilia : the Official Journal of the World Federation of Hemophilia·R SaxenaM Bhargava
Jul 6, 2000·Immunopharmacology·A C Allison, E M Eugui
Dec 21, 2000·Haemophilia : the Official Journal of the World Federation of Hemophilia·E CarlborgE Berntorp
Jun 16, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·Z L JiangP R Clemens
Jun 16, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·C H MiaoX Ye
Jul 10, 2001·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·P NeuhausJ M Langrehr
Sep 14, 2001·Advances in Experimental Medicine and Biology·M T RedingB M Conti-Fine
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Oct 18, 2002·Blood·Adrian WiestnerGeraldine P Schechter
Mar 18, 2003·Seminars in Thrombosis and Hemostasis·Guglielmo MarianiBarbara L Kroner
Jul 3, 2004·Lupus·M Dall'Era, J Davis
Jul 3, 2004·Lupus·J Yazdany, J Davis
Jul 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Peiqing YeCarol H Miao
Apr 9, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Gang MaiLeo H Bühler

❮ Previous
Next ❯

Citations

Feb 3, 2009·Clinical Reviews in Allergy & Immunology·Kathleen P Pratt, Arthur R Thompson
Feb 10, 2009·Clinical Reviews in Allergy & Immunology·Ai Hong ZhangDavid W Scott
Jul 9, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Valder R ArrudaJonathan D Finn
Nov 30, 2007·Gene Therapy·A Zaldumbide, R C Hoeben
Feb 22, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xiucui MaKatherine P Ponder
Mar 28, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Christopher B DoeringH Trent Spencer
Oct 4, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Takeshi Suda, Dexi Liu
Jan 9, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Stéphanie LorainLuis Garcia
Mar 19, 2013·Blood·David W ScottCarol H Miao
Mar 5, 2011·Journal of Medical Internet Research·Beverly B GreenAndrea J Cook
Oct 12, 2015·Cellular Immunology·Xiaomei WangRoland W Herzog
Oct 27, 2010·Expert Review of Hematology·Carol H Miao
Sep 23, 2006·Expert Opinion on Biological Therapy·Shu Uin GanRoy Y Calne
Nov 8, 2011·British Journal of Haematology·David W Scott, Jay N Lozier
Feb 5, 2013·Haemophilia : the Official Journal of the World Federation of Hemophilia·L A ValentinoK Stine
May 19, 2011·Journal of Thrombosis and Haemostasis : JTH·B MoghimiR W Herzog
Jun 9, 2011·Journal of Thrombosis and Haemostasis : JTH·C H Miao
Feb 26, 2015·Blood·Jan Astermark
Dec 15, 2006·Gene Therapy·H Herweijer, J A Wolff
Apr 28, 2017·International Journal of Laboratory Hematology·J D Lai, D Lillicrap
Apr 9, 2020·Frontiers in Immunology·Simone Merlin, Antonia Follenzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.